Redcare Pharmacy's Stock Is Telling a Different Story Than Its Results

Redcare Pharmacy's shares drop 6.6% despite strong Q2 and raised guidance, as investors worry about growth sustainability and CEO transition.

For a company celebrating its 25th anniversary as Europe's largest online pharmacy, Redcare Pharmacy's share price is proving an awkward party guest. The stock has shed value after virtually every piece of positive news the company has released over the past month, leaving investors to puzzle over a widening gap between operational performance and market sentiment.

The disconnect is striking when laid out chronologically. Following the company's momentum-focused announcement roughly two weeks ago, shares fell 12.4 percent. The half-year results published about a month earlier were met with a 9.6 percent decline. Even the anniversary communiqué from three weeks ago coincided with a 7.6 percent drop. Most recently, the stock lost 6.6 percent in a single session, closing at €57.00 — a move that pushed the shares below their 200-day moving average of €57.17 and roughly 12 percent under the 50-day average.

The Numbers Tell a Different Tale

None of this weakness reflects the underlying figures. Second-quarter revenue climbed 20 percent to €853 million, with the DACH region contributing 21 percent growth and international operations adding 17 percent. The adjusted EBITDA margin reached 3.5 percent — the strongest level in a decade — and the international segment posted its first-ever positive adjusted EBITDA. Active customers grew 9 percent to 14.7 million.

Management responded by lifting full-year guidance: revenue growth is now expected at 15 to 17 percent, up from the previous 13 to 15 percent range. The company also raised its forecast for German prescription (Rx) sales to between €680 million and €720 million, having previously guided for more than €617 million, while the EBITDA margin outlook was set at 2.5 to 3 percent.

The prescription business itself remains a growth engine, expanding 34 percent overall and an eye-catching 58 percent in Germany, with average Rx basket sizes up 14 percent.

Why the Market Isn't Buying

The caution appears rooted less in what the company has achieved than in what comes next. Management acknowledged that July growth came in slightly below the quarter's 20 percent pace, with the German non-prescription business decelerating to single-digit growth. Seasonal factors were cited, along with regulatory tailwinds — a fee adjustment effective July 1 and a more favorable pharmacy operating ordinance expected in August.

There is also the matter of the prescription bonus introduced in 2025. The comparison effect from that initiative will fade in the second half, and the company itself has conceded that Rx growth is likely to moderate noticeably. Investors may be reading the strong Q2 figures as a peak rather than confirmation of a sustainable trend.

Technical indicators reinforce the picture of a stock in transition. The relative strength index sits at 37.3, suggesting oversold conditions without necessarily implying a bottom. Annualized volatility of 49 percent underscores just how jittery trading has become.

Leadership Change Adds Another Variable

Adding to the mix, Peter Schmid von Linstow will take over as CEO on October 1, succeeding Olaf Heinrich, who steps down after three years and will remain available in an advisory capacity. The supervisory board announced the transition in late August, with shareholders set to formally confirm the appointment at the annual meeting on October 14.

Schmid von Linstow, who joined the board in April, brings more than two decades of leadership experience across digital platform businesses, including stints at Visable, Parship, eBay and AutoScout24. The handover appears orderly and long-planned — hardly the stuff of a major selloff. Yet it adds another layer of uncertainty to a stock already wrestling with questions about growth durability.

A Structural Story Waiting for Validation

The company is in the midst of genuine structural change as pharmaceutical supply shifts increasingly digital. Its Sevenum automation project, a central logistics initiative, remains on track for completion in early 2027 and should further improve the cost base. Investors will have opportunities in September to hear management's latest thinking at conferences in London, Zurich and Munich.

Whether that restores confidence remains an open question. The market capitalization of €1.25 billion looks modest against quarterly revenue of more than €850 million — a valuation that suggests investors are pricing in considerable skepticism about the sustainability of the growth trajectory once the prescription bonus effect dissipates.

Analyst estimates did turn slightly more optimistic following the quarterly results, with expected losses per share trimmed from €0.72 to €0.60. But such automated consensus adjustments say more about sentiment than substance.

Until hard data from the second half answers the question of whether growth can hold without the one-off boost, the stock is likely to remain volatile — regardless of who sits in the executive suite. The October 14 annual meeting will confirm the leadership change, but it probably won't settle the larger debate about what this 25-year-old business is worth to a market that has yet to be convinced.